科研之友
微信
新浪微博
Facebook
分享链接
摘要
Currently approved antiplatelet treatment strategies have proved successful for reducing cardiovascular adverse events in patients with CAD However, despite the use of recommended antiplatelet treatment strategies, the presence of DM has been consistently associated with a negative impact on outcomes and a high rate of adverse cardiovascular events continue to occur in patients with DM The elevated prevalence of low response to standard oral antiplatelet agents contribute to these impaired outcomes Thus, the search for more potent antiplatelet treatment strategies is warranted in high-risk patients, such as those with DM The present manuscript provides an overview on the current status of knowledge on currently available antiplatelet agents, focusing on the benefits and limitations of these therapies in DM patients, and evaluating the potential role of new antithrombotic agents and treatment strategies currently under development to overcome these limitations
- 出版日期2010-10
